

Starpharma to commence DEP[®] cabazitaxel phase 1/2 trial

Melbourne, Australia; 31 January 2018: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has received regulatory and ethics approvals to commence its phase 1/2 clinical trial for DEP[®] cabazitaxel. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP[®] cabazitaxel, to define a recommended phase 2 dose (RP2D), and then to determine anti-tumour efficacy of the product in select tumour types.

The trial will be conducted at multiple sites, with Guy's Hospital London and University College London Hospital (UCLH) in the UK being the first sites to open for recruitment. Further sites will open and commence recruitment as dose escalation progresses and the phase 2 part of the trial gets underway. Approximately 35 patients will be enrolled across the phase 1/2 trial.

DEP[®] cabazitaxel is Starpharma's detergent-free version of cancer drug, Jevtana[®], which is marketed by Sanofi Aventis to treat advanced prostate cancer, and is also under clinical development for a range of other cancer types, including testicular, ovarian, breast, bladder, and head and neck. Jevtana[®] sales are estimated to reach approximately US\$500 million this year.

DEP[®] cabazitaxel is the second product from Starpharma's DEP[®] platform to enter the clinic, and follows DEP[®] docetaxel, which delivered positive phase 1 clinical results in 2017 and recently progressed to phase 2. The reproducible benefits observed for DEP[®] docetaxel and DEP[®] cabazitaxel in preclinical models include decreased bone marrow toxicity and enhanced efficacy, and in both cases DEP[®] has also allowed for a detergent-free formulation resulting in significant additional benefits for patients.

In parallel, AstraZeneca's first DEP[®] product, AZD0466, has been developed under licence with Starpharma and has also demonstrated preclinical improvements consistent with findings for DEP[®] docetaxel and DEP[®] cabazitaxel.

The phase 1/2 study for DEP[®] cabazitaxel will enrol patients with advanced solid tumours and is an open-label study. In phase 1, DEP[®] cabazitaxel will be administered once every three weeks at escalating doses to determine if there are any Dose Limiting Toxicities (DLTs) and to establish the Maximum Tolerated Dose (MTD). The characterisation of the safety, tolerability and PK profile of DEP[®] cabazitaxel will help establish and characterise the RP2D.

In phase 2, the study will initially enrol up to 20 patients at the RP2D to determine the anti-tumour efficacy of DEP[®] cabazitaxel in specific tumour types, and to further characterise the safety, tolerability and PK of the product.

The adaptive trial design employed enables Starpharma to move seamlessly from phase 1 to phase 2 and to explore efficacy as early as possible. As the trial progresses, decisions will be made as to which tumour types to focus on and any additional patients required to further characterise efficacy in specific tumour types.

Dr Jackie Fairley, Starpharma CEO, commented: "We are delighted to advance DEP[®] cabazitaxel – our second DEP[®] product from our internal portfolio to the clinic. DEP[®] cabazitaxel has already delivered exciting preclinical results showing sustained efficacy and survival benefits, as well as eliminating neutropenia, which is a significant dose-limiting side effect of many anti-cancer drugs, including Jevtana[®]."

“These benefits for DEP[®] cabazitaxel are consistent with the recent positive phase 1 results for our lead internal DEP[®] product, DEP[®] docetaxel and findings in partnered DEP[®] programs. The growing body of data from our DEP[®] products illustrates the broad applicability of the DEP[®] platform and the compelling commercial advantages of enhancing drug performance and reducing toxicity for patients, while extending patent life”, concluded Dr Fairley.

About DEP[®] cabazitaxel

Starpharma’s DEP[®] platform was utilised to create DEP[®] cabazitaxel, a detergent free version of cancer drug Jevtana[®]. Jevtana[®] is a leading oncology agency which is used to treat advanced prostate cancer and also under development for other cancers including breast cancer, bladder cancer and head and neck cancer. The current (non-dendrimer) formulation product has US Food and Drug Administration (FDA)-mandated ‘black box’ warnings in relation to neutropenia, which is a major dose limiting side effect, and severe hypersensitivity (e.g. anaphylaxis) resulting from the polysorbate 80 detergent used in its formulation.

DEP[®] cabazitaxel significantly outperformed Jevtana[®] in a human breast cancer model with respect to both level and duration of anti-cancer activity and survival, whilst protecting against the development of neutropenia, which is a serious side effect for Jevtana[®].

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel[®] portfolio and DEP[®] drug delivery with the Company developing a number of products internally and others via commercial partnerships.

VivaGel[®]: Starpharma’s portfolio includes women’s health products based on VivaGel[®] (SPL7013, astodimer sodium), a proprietary dendrimer. VivaGel[®] BV is approved for marketing in the EU and Australia for bacterial vaginosis (BV). Starpharma has a license agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel[®] BV in Australia and New Zealand. Starpharma has also developed an antiviral condom which uses VivaGel[®] in the lubricant, which is available in Australia and Canada under the Lifestyles[®] Dual Protect™ brand. Starpharma has a number of license agreements to market the VivaGel[®] condom in other regions, including China and Japan (Okamoto).

DEP[®] - Dendrimer Enhanced Product[®]: Starpharma’s DEP[®] drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP[®] programs, including improved efficacy, safety and survival. Starpharma has two internal DEP[®] products – DEP[®] docetaxel and DEP[®] cabazitaxel - in clinical development in patients with solid tumours, and further DEP[®] products approaching clinical development. Starpharma’s partnered DEP[®] programs include a multiproduct DEP[®] licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more.

Starpharma.com | [Twitter](https://twitter.com/Starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

Media

WE Buchan Consulting

Rebecca Wilson
Mob: +61 417 382 391
wilson@buchanwe.com.au

Arthur Chan
+61 2 9237 2805
achan@buchanwe.com.au

Starpharma

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.